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Outbreaks of Ebola hemorrhagic fever in sub-Saharan Africa are associated with case fatality rates of up to
90%. Currently, neither a vaccine nor an effective antiviral treatment is available for use in humans. Here,
we evaluated the efﬁcacy of the pyrazinecarboxamide derivative T-705 (favipiravir) against Zaire Ebola
virus (EBOV) in vitro and in vivo. T-705 suppressed replication of Zaire EBOV in cell culture by 4 log units
with an IC90 of 110 lM. Mice lacking the type I interferon receptor (IFNAR/) were used as in vivo model
for Zaire EBOV-induced disease. Initiation of T-705 administration at day 6 post infection induced rapid
virus clearance, reduced biochemical parameters of disease severity, and prevented a lethal outcome in
100% of the animals. The ﬁndings suggest that T-705 is a candidate for treatment of Ebola hemorrhagic
fever.
 2014 The Authors. Published by Elsevier B.V. Open access under CC BY license.Filoviruses of the genus Ebolavirus comprise four virus species
that cause hemorrhagic fever in humans with case-fatality rates
of up to 90%. Since the ﬁrst documented outbreak of Zaire Ebola
virus (EBOV) in 1976 in the Democratic Republic of Congo (for-
merly Zaire), EBOV has caused outbreaks in several sub-Saharan
African countries. Ebola hemorrhagic fever (EHF) is characterized
by host immunosuppression, high viremia, and multiorgan failure
resembling septic shock. Several vaccine candidates including DNA
vaccines, vectored vaccines, and virus-like particles-based vaccines
have shown efﬁcacy in non-human primate models of EHF. How-
ever, no EBOV vaccine is currently licensed for application in hu-
mans (for a review, see Feldmann and Geisbert, 2011).
Drug candidates such as rNAPc2 (Geisbert et al., 2003), estrogen
receptor modulators (Johansen et al., 2013), siRNA (Geisbert et al.,
2010), interferon (IFN) (Smith et al., 2013), or neutralizing mono-
clonal antibodies (Olinger et al., 2012; Qiu et al., 2012) have shown
protection when administered shortly after infection. However,
none of them had a therapeutic beneﬁt beyond the time window
of 2 days post infection. The vesicular stomatitis virus-vectored
vaccine expressing the EBOV glycoprotein demonstrated a similarpost exposure protection (Feldmann et al., 2007). Combination of
monoclonal antibodies with adenovirus-vectored IFN-alpha has re-
cently extended the treatment window to 3 days post-exposure
when early viremia and symptoms were already detectable (Qiu
et al., 2013). Despite the major success so far, the therapeutic win-
dow to treat EBOV disease is still narrow highlighting the necessity
to develop strategies for clinical management of symptomatic EHF
beyond supportive therapy.
The pyrazinecarboxamide derivative T-705 (favipiravir) was
published in 2002 by Toyama Chemicals (Japan) as an inhibitor
of inﬂuenza virus replication (Furuta et al., 2002) and is currently
in late stage clinical development for the treatment of ﬂu (for a
review, see Furuta et al., 2013). It is converted by host enzymes
to T-705-ribofuranosyl-50-triphosphate and presumably acts as a
nucleotide analog that selectively inhibits the viral RNA-
dependent RNA polymerase or causes lethal mutagenesis upon
incorporation into the virus RNA (Baranovich et al., 2013; Furuta
et al., 2005; Jin et al., 2013; Naesens et al., 2013; Smee et al.,
2009). Besides inﬂuenza virus (Furuta et al., 2002), T-705 has
shown potent antiviral activity against other segmented
negative-strand RNA viruses such as arena- and bunyaviruses
in vitro and in vivo (Gowen et al., 2007; Safronetz et al., 2013).
In addition, T-705 has also demonstrated activity against
positive-strand RNA viruses such as noro- and ﬂaviviruses
(Morrey et al., 2008; Rocha-Pereira et al., 2012).
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to determine the effect of T-705 against EBOV, a negative strand
RNA virus belonging to the order of Mononegavirales. The T-705
compound (favipiravir; CAS No. 259793-96-9; PubChem CID
492405) was custom synthesized by BOC Science, Creative Dynam-
ics, USA, dissolved in dimethyl sulfoxide (DMSO) at a concentration
of 10 mg/ml, and stored at 20 C. All experiments were conducted
in the biosafety level 4 (BSL-4) laboratory at the Bernhard-Nocht-
Institute for Tropical Medicine in Hamburg using the wild-type
Zaire EBOV Mayinga 1976 strain. It had been provided around
1980 by the Center for Disease Control, Atlanta, Georgia. The pas-
sage history since 1976 is not documented. To deﬁne our strain
precisely, it has been completely sequenced. The sequence is iden-
tical to that of Zaire EBOVMayinga 1976 strain (GenBank accession
No. NC_002549) except of two differences: C1751T changing
nucleoprotein codon CCC (Pro) to TCC (Ser), and G6175A changing
glycoprotein codon AGT (Ser) to AAT (Asn). The virus stock was
grown on Vero E6 cells (ATCC No. CRL-1586), quantiﬁed by immu-
nofocus assay (see below), and stored at 70 C until use in in vitro
and in vivo experiments.
First, we evaluated the antiviral activity of T-705 in cell culture.
The compound was added to Vero E6 cells infected one hour before
with EBOV at a multiplicity of infection of 0.01. Final DMSO con-
centration in the cell culture supernatant was 0.1%. Five days post
infection (p.i.) the concentration of infectious EBOV particles in cell
culture supernatant was determined by immunofocus assay using
polyclonal monkey anti-EBOV (kindly provided by Pierre Rollin) for
detection of infected foci as described (Günther et al., 2004). Cell
viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-2H-tetrazoliumbromide (MTT) method as described
(Günther et al., 2004). T-705 was able to suppress EBOV replication
by 4 log10 units (Fig. 1A) with an inhibitory concentration that re-
duced the virus titer by 50% (IC50) of 67 lM (10 lg/ml) (Fig. 1B),
which is in the same order of magnitude than the IC50 for the only
member of the orderMononegavirales tested so far, namely respira-
tory syncytial virus (RSV; IC50 = 41 lg/ml) (Furuta et al., 2002).
T-705 treatment did not affect cell viability in the test range asFig. 1. Antiviral activity of T-705 against EBOV in cell culture. (A) Vero E6 cells were
infected with EBOV and T-705 was added 1 h p.i. After 5 days, the concentration of
infectious viral particles in the cell culture supernatant was measured by
immunofocus assay. A sigmoidal dose–response curve was ﬁtted to the data using
Prism GraphPad 6.0 (GraphPad Software). Cell viability was measured by the MTT
method. (B) The IC50, IC90 and IC99 values for T-705 with 95% conﬁdence interval
(95% CI) were calculated from the sigmoidal function.measured by MTT assay (cytotoxic concentration that reduced cell
growth by 50% > 1000 lM).
Next, we addressed the therapeutic efﬁcacy of T-705 in a small
animal model. To this end, we used mice lacking the type I IFN-al-
pha/beta receptor (IFNAR/), which have been shown to be sus-
ceptible to infection with wild-type Zaire 1976 EBOV (Bray,
2001; Lever et al., 2012). To rule out effects related to the mouse
genetic background, both IFNAR/ C57BL/6 and IFNAR/ 129/Sv
mice were used. All animal experiments were carried out in the
BSL-4 animal facility in strict accordance with the recommenda-
tions of the German Society for Laboratory Animal Science under
supervision of a veterinarian. The protocol had been approved by
the Committee on the Ethics of Animal Experiments of the City
of Hamburg (Permit No. 44/11). All staff carrying out animal exper-
iments has passed an education and training program according to
category B or C of the Federation of European Laboratory Animal
Science Associations. The experimental groups contained 5–10
age-matched female mice. Natural mucosal exposure to EBOV
was mimicked by intranasal inoculation of 1000 focus-forming
units (FFU) of EBOV diluted in 50 ll phosphate-buffered saline
(PBS). T-705 was administered in 0.5% methylcellulose twice daily
per os using a stomach probe.
In IFNAR/ C57BL/6 mice, treatment [300 mg/(kg  d)] was ini-
tiated 6 days p.i. or later. As expected, EBOV infection of untreated
mice resulted in 100% lethality within 10 days after infection
(Fig. 2, left panel). All mice lost weight rapidly and some of them
reached the limit of humane endpoint established in our approved
animal protocol (20% weight loss). Strong elevation of serum
aspartate and alanine aminotransferase (AST and ALT) levels up
to 10,000 U/l — a hallmark of EHF in humans (Rollin et al., 2007)
— high viremia up to 6 log10 FFU/ml, and substantial decrease of
body temperature below 32 C consistent with shock were ob-
served in untreated mice (Fig. 2, left panel). Until the ﬁrst day of
treatment (day 6 p.i.), all mice in the T-705 group lost weight sim-
ilarly to control mice, developed viremia, and showed elevated ser-
um levels of AST and ALT indicating symptomatic EBOV infection
(Fig. 2, middle panel). Already two days after initiation of treat-
ment (day 8 p.i.), levels of AST, ALT, and viremia dropped signiﬁ-
cantly in treated mice relative to the controls (p = 0.0025,
p = 0.0043, and p = 0.0025, respectively; Mann–Whitney U test)
(Fig. 2, middle panel). Within four days of T-705 treatment (day
10 p.i.), the animals had cleared the virus from blood. Treatment
was continued until day 13, and at the end of the 3-weeks obser-
vation period, all mice recovered (100% survival vs. 100% fatality
rate among controls, p = 0.00033; 2-tailed Fisher’s Exact Test). All
surviving mice developed EBOV-speciﬁc antibodies as tested by
immunoﬂuorescence assay and CD8 T cells speciﬁc for the viral
nucleoprotein (data not shown), suggesting that suppression of
virus replication by T-705 allowed the host to mount a virus-spe-
ciﬁc adaptive immune response, even in the absence of functional
type I IFN signaling.
To determine the therapeutic window for T-705 treatment,
300 mg/(kg  d) were also administered to a group of mice begin-
ning at day 8 p.i. (Fig. 2, right panel). At this time, all animals
showed peak levels of AST, ALT, and viremia, and reduced body
temperature. Loss of body weight was evident and close to the hu-
mane endpoint. T-705 treatment delayed death and reduced virus
load and biochemical correlates of disease in 1/5 (20%) mice even
at this terminal stage, but did not prevent death. Thus, in the
IFNAR/ C57BL/6 mouse model, T-705 was 100% effective in the
treatment of Zaire EBOV infection up to 6 days p.i. when high vire-
mia and overt signs of disease are present, but was hardly beneﬁ-
cial at the terminal stage of the disease.
IFNAR/ 129/Sv mice received either 30 mg/(kg  d) from days
2 to 9 or 300 mg/(kg  d) from days 2 to 9, days 4 to 11, or days 6 to
13. Surprisingly, despite clear clinical and biochemical signs of
Fig. 2. Treatment of EBOV-infected IFNAR/ C57BL/6 mice with T-705. Groups of 5 mice were inoculated intranasally with 1000 FFU of EBOV. Mice were treated with a T-705
dose of 300 mg/(kg  d). The drug was administered twice daily per os using a stomach probe. Placebo mice received no treatment. Treatment was performed for the period
indicated above the columns (shaded in gray with the survival curves). Survival was determined using Kaplan–Meier analysis. The humane endpoint established in our
animal protocol was reached by 10/10 of the control group and 4/5 of the day-8 treatment group; one animal was found dead. Relative weight, temperature, AST, ALT, and log-
transformed virus titers in blood are shown as mean with standard deviation. Treatment duration, normal ranges for AST and ALT, and the range of viremia below the limit of
detection of the immunofocus assay are shaded in gray. Statistical analysis for treatment at days 6–13 vs. controls: (i) weight and temperature were tested with two-way
ANOVA (treatment [yes and no] vs. time [days 7, 8, and 9]) (weight: treatment p = 0.02, time p = 0.0001, interaction p < 0.0001; temperature: treatment p = 0.13, time
p = 0.001, interaction p = 0.007) and t-test for day 9 (weight p = 0.00017; temperature p = 0.03), (ii) AST, ALT, and log-transformed viremia were tested at day 8 by Mann–
Whitney U test (p = 0.0025, p = 0.0043, and p = 0.0025, respectively) and, as the values were found to be normally distributed, also by t-test (p = 0.001, p < 0.0001, and
p < 0.0001, respectively), and (iii) survival was tested by Fisher’s Exact Test (p = 0.00033) and log-rank (Mantel–Cox) test (p = 0.0008). Statistical analysis for treatment at days
8–14 vs. controls did not reveal any signiﬁcant associations. The p values of the ANOVA interaction, the t-test, and the log-rank test are shown in the ﬁgure (⁄p < 0.05,
⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, ****p < 0.0001, n.s., not signiﬁcant).
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(Fig. 3). This is in contrast with previous results indicating that
aerosolized Zaire 1976 EBOV is uniformly lethal for IFNAR/
129/Sv mice (Lever et al., 2012). Differences in the virus strain used
(Zaire EBOV E718 1976 strain compared to Mayinga strain in our
study) may account for these contradictory ﬁndings. In addition,
the study by Lever et al. used a Collison nebulizer to generate par-
ticles predominantly 1–3 lm in diameter, which may result inFig. 3. Treatment of EBOV-infected IFNAR/ 129/Sv mice with T-705. Groups of 5–8 mic
705 dose of 30 or 300 mg/(kg  d). The drug was administered twice daily per os using
daily. Treatment was performed for the period indicated above the columns (shaded in gr
The humane endpoint established in our animal protocol was reached by 2/8 of the contr
blood are shown as mean with standard deviation. Treatment duration, normal range
immunofocus assay are shaded in gray. Statistical analysis for treatment vs. controls: (i)
vs. time [each day under treatment until day 8 p.i.]), (ii) AST, ALT, and log-transformed vi
Fisher’s Exact Test (n.s.) and log-rank (Mantel–Cox) test (n.s.). The p values of the ANO
**p < 0.01, ***p < 0.001, ****p < 0.0001, n.s., not signiﬁcant).deposition of virus particles deeper in the respiratory tract com-
pared to intranasal inoculation. As shown in Fig. 3, untreated mice
showed serum AST levels of 352–9500 U/l and ALT levels of 210–
2,400 U/l at day 8 p.i. Conversely, all T-705-treated mice had signif-
icantly reduced AST and ALT levels (p = 0.0016–0.0031 and
p = 0.001–0.002 respectively; Mann–Whitney U test). In addition,
while the mean virus load in blood at day 8 p.i. was
5.1  105 FFU/ml for untreated mice, no virus was detectable ine were inoculated intranasally with 1000 FFU of EBOV. Mice were treated with a T-
a stomach probe. Placebo treated mice received 100 ll 0.5% methylcellulose twice
ay with the survival curves). Survival was determined using Kaplan–Meier analysis.
ol group. Relative weight, temperature, AST, ALT, and log-transformed virus titers in
s for AST and ALT, and the range of viremia below the limit of detection of the
weight and temperature were tested with two-way ANOVA (treatment [yes and no]
remia were tested at day 8 by Mann–Whitney U test, and (iii) survival was tested by
VA interaction, the t-test, and the log-rank test are shown in the ﬁgure (*p < 0.05,
L. Oestereich et al. / Antiviral Research 105 (2014) 17–21 21mice treated with T-705 irrespective of the dose or the time point
for initiation of treatment (p = 0.02–0.0055; Mann–Whitney U
test). The differences in survival, weight loss, and body tempera-
ture at day 8 p.i. were not statistically signiﬁcant between the
experimental groups. Similarly to C57BL/6 mice, all surviving
129/Sv mice developed EBOV-speciﬁc antibodies and CD8 T cells
(data not shown).
To the best of our knowledge, T-705 represents the ﬁrst effec-
tive therapeutic agent for advanced Zaire EBOV infection in an ani-
mal model. It reduces viremia, ameliorates clinical and biochemical
signs of disease, and prevents lethal outcome in 100% of the ani-
mals if treatment is commenced 6 days after infection, which cor-
responds to 2–4 days before the time of death in control animals.
Our study is consistent with and extends a parallel study just in
press showing that T-705 prevents death of IFNAR/ 129/Sv mice
when given 1 h after aerosol challenge with EBOV (Smither et al.,
2014). T-705 has the additional advantage that it is capable of
reducing EBOV viremia following oral administration. This is com-
parable to ribavirin, which can be given orally to treat other hem-
orrhagic fevers such as Lassa fever (McCormick et al., 1986), but is
ineffective against ﬁloviruses (Feldmann and Geisbert, 2011). The
data further indicate that T-705 is active in vivo against viruses
of the order Mononegavirales, which comprise a multitude of hu-
man pathogens. The only previous example, the paramyxovirus
RSV, was shown to be less susceptible to T-705 than segmented
negative strand RNA viruses in vitro, which somewhat reduced
optimism regarding the putative use of T-705 against non-seg-
mented negative strand RNA viruses (Furuta et al., 2002). The
IC50 of T-705 for EBOV is also higher than that for inﬂuenza or are-
naviruses (Furuta et al., 2002; Gowen et al., 2007). Nevertheless,
the drug shows clear effects in vivo which holds promise for
in vivo efﬁcacy of T-705 against other viruses, which are inhibited
in vitro only at rather high drug concentration. In the case of EBOV
infection, we speculate that the suppression of virus replication by
T-705 in vivo allows the adaptive arm of the host immune system
to tackle viral infection effectively and thus to contribute to the
therapeutic effect of T-705. This is in line with previous data indi-
cating an association between the level of EBOV viremia and the
strength of the host immune response (Leroy et al., 2001). Further
experiments to determine the involvement of immune responses
in the context of T-705 treatment are under way. T-705 has been
shown to be effective at inhibiting replication of RNA viruses in
various small animal models (Furuta et al., 2002; Gowen et al.,
2007; Morrey et al., 2008; Safronetz et al., 2013). This, together
with our data generates cautious optimism about the translation
of our ﬁndings into more realistic EHF models such as non-human
primates, and eventually clinical practice.
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